Figures & data
Table 1. Summary of key model components.
Figure 1. Kaplan–Meier estimates of OS for ruxolitinib and BAT with (RPSFT) and without (original) cross-over correction.
Figure 2. Observed (points) and estimated (shadowed area under the curve) proportion of patients with zero, one or two or more transfusions per cycle of 4 weeks for MF patients treated with ruxolitinib or BAT.
Figure 3. Cost-effectiveness acceptability curve showing the probability of ruxolitinib being cost-effective over a range of values for the maximum willingness-to-pay per life year gained.
